-- Diverse, late-stage specialty therapeutics and diabetes management
device pipeline with one FDA-approved product, a therapeutic
dermatology product candidate covered by a pending NDA filed with the
FDA and ten (10) product development programs;
-- Flexible, strategic partnership with Cato Research, an established
global contract research organization (CRO), to maximize development
and regulatory efficiencies; and,
-- Expertise from Cato Research to expand the reach of ongoing late-stage
clinical development programs in continuous transdermal glucose
About Echo Therapeutics
Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical reformulations of FDA-approved products and a portfolio of next generation wireless, needle-free continuous transdermal glucose monitor (CTGM) systems for the diabetes home use and hospital intensive and critical care markets. Echo is also developing a broad portfolio of advanced topical reformulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead AzoneTS-based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses. Echo's next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform.
SonoPrep is a registered trademark of Echo Therapeutics, Inc.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subjec
|SOURCE Echo Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved